Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

35 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Exploring resistance pathways for first-generation NS3/4A protease inhibitors boceprevir and telaprevir using Bayesian network learning.
Cuypers L, Libin P, Schrooten Y, Theys K, Di Maio VC, Cento V, Lunar MM, Nevens F, Poljak M, Ceccherini-Silberstein F, Nowé A, Van Laethem K, Vandamme AM. Cuypers L, et al. Among authors: di maio vc. Infect Genet Evol. 2017 Sep;53:15-23. doi: 10.1016/j.meegid.2017.05.007. Epub 2017 May 9. Infect Genet Evol. 2017. PMID: 28499845
Implications of hepatitis C virus subtype 1a migration patterns for virus genetic sequencing policies in Italy.
Cuypers L, Vrancken B, Fabeni L, Marascio N, Cento V, Di Maio VC, Aragri M, Pineda-Peña AC, Schrooten Y, Van Laethem K, Balog D, Focà A, Torti C, Nevens F, Perno CF, Vandamme AM, Ceccherini-Silberstein F. Cuypers L, et al. Among authors: di maio vc. BMC Evol Biol. 2017 Mar 7;17(1):70. doi: 10.1186/s12862-017-0913-3. BMC Evol Biol. 2017. PMID: 28270091 Free PMC article.
Hepatitis C virus RNA levels at week-2 of telaprevir/boceprevir administration are predictive of virological outcome.
Cento V, Di Paolo D, Di Carlo D, Micheli V, Tontodonati M, De Leonardis F, Aragri M, Antonucci FP, Di Maio VC, Mancon A, Lenci I, Manunta A, Taliani G, Di Biagio A, Nicolini LA, Nosotti L, Sarrecchia C, Siciliano M, Landonio S, Pellicelli A, Gasbarrini A, Vecchiet J, Magni CF, Babudieri S, Mura MS, Andreoni M, Parruti G, Rizzardini G, Angelico M, Perno CF, Ceccherini-Silberstein F. Cento V, et al. Among authors: di maio vc, di biagio a, di paolo d, di carlo d. Dig Liver Dis. 2015 Feb;47(2):157-63. doi: 10.1016/j.dld.2014.11.010. Epub 2014 Nov 24. Dig Liver Dis. 2015. PMID: 25544656 Free article.
Kinetics of hepatitis C virus RNA decay, quasispecies evolution and risk of virological failure during telaprevir-based triple therapy in clinical practice.
Cento V, Tontodonati M, Di Maio VC, Bellocchi MC, Valenti F, Manunta A, Fortuna S, Armenia D, Carioti L, Antonucci FP, Bertoli A, Trave F, Cacciatore P, Angelico M, Navarra P, Neumann AU, Vecchiet J, Parruti G, Babudieri S, Perno CF, Ceccherini-Silberstein F. Cento V, et al. Among authors: di maio vc. Dig Liver Dis. 2015 Mar;47(3):233-41. doi: 10.1016/j.dld.2014.12.004. Epub 2014 Dec 27. Dig Liver Dis. 2015. PMID: 25637450
Viral resistance in HCV infection.
Ceccherini-Silberstein F, Cento V, Di Maio VC, Perno CF, Craxì A. Ceccherini-Silberstein F, et al. Among authors: di maio vc. Curr Opin Virol. 2018 Oct;32:115-127. doi: 10.1016/j.coviro.2018.10.005. Epub 2018 Nov 12. Curr Opin Virol. 2018. PMID: 30439589 Review.
Hepatitis C virus genetic variability and the presence of NS5B resistance-associated mutations as natural polymorphisms in selected genotypes could affect the response to NS5B inhibitors.
Di Maio VC, Cento V, Mirabelli C, Artese A, Costa G, Alcaro S, Perno CF, Ceccherini-Silberstein F. Di Maio VC, et al. Antimicrob Agents Chemother. 2014 May;58(5):2781-97. doi: 10.1128/AAC.02386-13. Epub 2014 Mar 3. Antimicrob Agents Chemother. 2014. PMID: 24590484 Free PMC article.
Anti-HBV treatment induces novel reverse transcriptase mutations with reflective effect on HBV S antigen.
Cento V, Van Hemert F, Neumann-Fraune M, Mirabelli C, Di Maio VC, Salpini R, Bertoli A, Micheli V, Gubertini G, Romano S, Visca M, De Sanctis GM, Berkhout B, Marino N, Mazzotta F, Cappiello G, Spanò A, Sarrecchia C, Ceccherini-Silberstein F, Andreoni M, Angelico M, Verheyen J, Perno CF, Svicher V. Cento V, et al. Among authors: di maio vc. J Infect. 2013 Oct;67(4):303-12. doi: 10.1016/j.jinf.2013.05.008. Epub 2013 Jun 22. J Infect. 2013. PMID: 23796863
Optimal cure rate by personalized HCV regimens in real-life: a proof-of-concept study.
Cento V, Aragri M, Teti E, Polilli E, Bertoli A, Foroghi L, Barbaliscia S, Di Maio VC, Pieri A, Pace Palitti V, Sarmati L, Parruti G, Andreoni M, Perno CF, Ceccherini-Silberstein F. Cento V, et al. Among authors: di maio vc. J Antimicrob Chemother. 2017 Dec 1;72(12):3420-3424. doi: 10.1093/jac/dkx302. J Antimicrob Chemother. 2017. PMID: 28961921 Free article.
Successful ongoing retreatment with glecaprevir/pibrentasvir + sofosbuvir + ribavirin in a patient with HCV genotype 3 who failed glecaprevir/pibrentasvir with both NS3 and NS5A resistance.
Aragri M, Milana M, Di Maio VC, Lenci I, Carioti L, Perno CF, Svicher V, Angelico M, Ceccherini-Silberstein F. Aragri M, et al. Among authors: di maio vc. Clin Microbiol Infect. 2020 Sep;26(9):1266-1268. doi: 10.1016/j.cmi.2020.03.022. Epub 2020 Mar 30. Clin Microbiol Infect. 2020. PMID: 32240711 Free article. No abstract available.
35 results